Replimune Group, Inc. (REPL)
14.69
-0.08
(-0.54%)
USD |
NASDAQ |
Aug 24, 16:00
14.69
0.00 (0.00%)
After-Hours: 20:00
Replimune Group Debt to Equity Ratio : 1.060 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.060 |
| March 31, 2026 | 0.6716 |
| December 31, 2025 | 0.3626 |
| September 30, 2025 | 0.2898 |
| June 30, 2025 | 0.2267 |
| March 31, 2025 | 0.1832 |
| December 31, 2024 | 0.1576 |
| September 30, 2024 | 0.1996 |
| June 30, 2024 | 0.1781 |
| March 31, 2024 | 0.2026 |
| December 31, 2023 | 0.1798 |
| September 30, 2023 | 0.1306 |
| June 30, 2023 | 0.1184 |
| March 31, 2023 | 0.1094 |
| December 31, 2022 | 0.1015 |
| September 30, 2022 | 0.0835 |
| June 30, 2022 | 0.0791 |
| March 31, 2022 | 0.0799 |
| December 31, 2021 | 0.0756 |
| Date | Value |
|---|---|
| September 30, 2021 | 0.0719 |
| June 30, 2021 | 0.0692 |
| March 31, 2021 | 0.0667 |
| December 31, 2020 | 0.0647 |
| September 30, 2020 | 0.1654 |
| June 30, 2020 | 0.1553 |
| March 31, 2020 | 0.2275 |
| December 31, 2019 | 0.2128 |
| September 30, 2019 | 0.1615 |
| June 30, 2019 | 0.0056 |
| March 31, 2019 | 0.0476 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Moderna, Inc. | 0.1904 |
| Kalaris Therapeutics, Inc. | 0.0243 |
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 252.45M |
| Total Liabilities (Quarterly) | 146.80M |
| Shareholders Equity (Quarterly) | 105.64M |
| Current Ratio | 5.228 |
| Net Debt Paydown Yield | -0.77% |